NASDAQ:CELU Celularity (CELU) Stock Price, News & Analysis $2.81 -0.03 (-1.06%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.58▼$2.8150-Day Range$2.72▼$3.1952-Week Range$1.59▼$7.97Volume6,952 shsAverage Volume114,108 shsMarket Capitalization$54.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Celularity alerts: Email Address Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Celularity Stock (NASDAQ:CELU)Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Read More CELU Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CELU Stock News HeadlinesSeptember 5 at 8:02 PM | markets.businessinsider.comCelularity to Present at H.C. Wainwright’s 26th Annual Global Investment ConferenceSeptember 5 at 4:05 PM | globenewswire.comCelularity to Present at H.C. Wainwright's 26th Annual Global Investment ConferenceSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.September 4 at 11:05 AM | markets.businessinsider.comUnlocking the Secrets of Immortality: KCSA Podcast Labs Dives into $43 Billion Longevity IndustryAugust 28, 2024 | globenewswire.comCelularity Appoints Richard J. Berman to its Board of DirectorsAugust 23, 2024 | globenewswire.comCelularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingAugust 11, 2024 | es.investing.comCelularity (CELU)July 31, 2024 | globenewswire.comCelularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023September 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.July 19, 2024 | finance.yahoo.comAmniotic Products Market Size to Hit US$ 1.67 Billion By 2032, Due to Rise in Patient Population & Surgical Interventions | Research by SNS InsiderJune 3, 2024 | globenewswire.comCelularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 24, 2024 | globenewswire.comCelularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingMay 14, 2024 | globenewswire.comCelularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T TherapyApril 22, 2024 | globenewswire.comCelularity Inc. to Host Investor and Analyst Research & Development DayApril 19, 2024 | globenewswire.comCelularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K FilingApril 18, 2024 | globenewswire.comCelularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024April 15, 2024 | globenewswire.comCelularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial ProductsApril 8, 2024 | globenewswire.comCelularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental CellsSee More Headlines Receive CELU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celularity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today9/07/2024Next Earnings (Estimated)9/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CELU CUSIPN/A CIK1752828 Webwww.celularity.com Phone908-768-2170FaxN/AEmployees220Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-196,290,000.00 Net Margins-862.04% Pretax Margin-861.99% Return on Equity27.63% Return on Assets10.48% Debt Debt-to-Equity RatioN/A Current Ratio0.29 Quick Ratio0.21 Sales & Book Value Annual Sales$22.77 million Price / Sales2.39 Cash Flow$6.85 per share Price / Cash Flow0.41 Book Value$2.11 per share Price / Book1.33Miscellaneous Outstanding Shares19,378,000Free Float15,367,000Market Cap$54.45 million OptionableOptionable Beta0.44 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Robert Joseph Hariri M.D. (Age 65)Ph.D., Founder, CEO & Chairman Comp: $1.24MMr. David C. Beers C.F.A. (Age 54)Chief Financial Officer Comp: $455.02kMr. John R. Haines (Age 66)Senior EVP, Global Manager & Chief Administrative Officer Comp: $503.56kRamji KrishnanChief Technology OfficerCarlos RamirezSVP of Investor RelationsMr. Kyle Harold Fletcher Esq. (Age 39)Executive VP, General Counsel & Chief Compliance Officer Dr. Stephen A. Brigido D.P.M. (Age 48)President of Degenerative Diseases Dr. Adrian Kilcoyne M.B.A. (Age 53)M.D., M.P.H., Executive VP, Chief Medical Officer and Head of Global Affairs, Patient Safety & Patient Affairs Sharmila Koppisetti M.D.Senior Vice President of Clinical Dev. Immunology & Drug SafetyMr. Tim WilkSenior Vice President of Technical OperationsMore ExecutivesKey CompetitorsATI Physical TherapyNYSE:ATIPMicrovastNASDAQ:MVSTCarLotzNASDAQ:LOTZTrevi TherapeuticsNASDAQ:TRVIProcaps GroupNASDAQ:PROCView All CompetitorsInsiders & InstitutionsRenaissance Technologies LLCSold 4,270 shares on 8/9/2024Ownership: 0.132%Keynote Financial Services LLCBought 15,566 shares on 6/13/2024Ownership: 0.080%Kok Thay LimBought 2,141,098 shares on 1/12/2024Total: $5.35 M ($2.50/share)Robert J HaririBought 935,758 shares on 10/5/2023Total: $1.50 M ($1.60/share)Robert J HaririBought 906,453 shares on 9/29/2023Total: $1.54 M ($1.70/share)View All Insider TransactionsView All Institutional Transactions CELU Stock Analysis - Frequently Asked Questions How have CELU shares performed this year? Celularity's stock was trading at $2.4740 on January 1st, 2024. Since then, CELU shares have increased by 13.6% and is now trading at $2.81. View the best growth stocks for 2024 here. How were Celularity's earnings last quarter? Celularity Inc. (NASDAQ:CELU) released its quarterly earnings data on Friday, November, 12th. The company reported $4.00 EPS for the quarter, topping the consensus estimate of ($3.50) by $7.50. The company earned $10.62 million during the quarter, compared to the consensus estimate of $3.46 million. Celularity had a negative net margin of 862.04% and a positive trailing twelve-month return on equity of 27.63%. When did Celularity's stock split? Shares of Celularity reverse split on the morning of Thursday, February 29th 2024. The 1-10 reverse split was announced on Thursday, February 29th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Celularity's major shareholders? Celularity's top institutional investors include Renaissance Technologies LLC (0.13%). Insiders that own company stock include Kok Thay Lim and Robert J Hariri. View institutional ownership trends. How do I buy shares of Celularity? Shares of CELU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CELU) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celularity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.